Thursday, October 5, 2017
54% ...
...
of WellCare members have access to Remicade, a DMARD used to treat ulcerative
colitis and other autoimmune diseases, on the specialty tier, with prior
authorizaton or step therapy. 24% of formularies do not cover Remicade, which
is known for its high cost, and only 6% place it on the preferred tier.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment